Summit Therapeutics Inc.
SMMT
$18.95
$0.291.55%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 301.60% | 445.48% | 399.25% | 2,509.44% | 35.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 192.01% | 242.80% | 301.20% | 1,174.24% | 57.71% |
| Operating Income | -192.01% | -242.80% | -301.20% | -1,174.24% | -57.71% |
| Income Before Tax | -201.09% | -258.11% | -312.05% | -836.84% | -44.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -201.09% | -258.11% | -312.05% | -836.84% | -44.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -201.09% | -258.11% | -312.05% | -836.84% | -44.72% |
| EBIT | -192.01% | -242.80% | -301.20% | -1,174.24% | -57.71% |
| EBITDA | -192.05% | -242.85% | -301.26% | -1,174.73% | -57.75% |
| EPS Basic | -186.74% | -244.58% | -302.84% | -793.08% | -37.64% |
| Normalized Basic EPS | -186.49% | -244.32% | -302.69% | -1,087.28% | -37.73% |
| EPS Diluted | -171.44% | -219.20% | -289.75% | -746.44% | -45.40% |
| Normalized Diluted EPS | -186.49% | -244.32% | -302.69% | -1,087.28% | -37.73% |
| Average Basic Shares Outstanding | 5.06% | 3.92% | 2.31% | 4.90% | 5.17% |
| Average Diluted Shares Outstanding | 5.06% | 3.92% | 2.31% | 4.90% | 5.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |